Posted by Michael Wonder on 08 Apr 2019
Prostate cancer hormone therapy rejected on NHS in England
8 April 2019 - A prostate cancer drug won't be offered on the NHS any earlier in the treatment plans of patients living with the disease in England, after it failed to pass a cost-effectiveness review.
Enzalutamide (Xtandi) is a type of hormone therapy that is already given to some people with prostate cancer that has spread to other parts of the body. But in new guidelines, the National Institute for Health and Care Excellence (NICE) rejected the drug for use in patients whose disease has stopped responding to other hormone treatments, but is less advanced and hasn't spread.
